



PATENT

Docket No. 2026-4205

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Topalian, et al.

Group Art unit: 1645

Serial No.

08/533,895

Examiner: Caputa, A.

Filed

September 26, 1995

For

MHC CLASS II RESTRICTED MELANOMA ANTIGENS

AND THEIR USE IN THERAPEUTIC METHODS

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.115

Assistant Commissioner for Patents Washington, D.C. 20231 Sir:

In response to the Official Action mailed April 29, 1998, applicants present the following amendments and remarks. Applicants have petitioned herewith and paid the fee for a three-month extension of time thereby extending the period for reply up to and including October 29, 1998.

IN THE CLAIMS

Please cancel claims 3-30, 56 and 61.

11/02/1998 NMARHOL 00000051 08533895 amend the claims as follows

02 FC:102

(amended)

An isolated MHC Class II immunogenic derivative of

tyrosinase, wherein said derivative [contains] comprises at least a 9 amino acid segment of a sequence selected from the group consisting of ONILLSNAPLGPQFP (Ty 56-70) (SEQ ID NO:

1), NILLSNAPLGPQFP (Ty 57-70) (SEQ ID/NO: 2) DYSYLQDSDPDSFQD (Ty 448-462)

427941 1